论文部分内容阅读
将80例2型糖尿病患者随机分为诺和锐30组和优泌乐50组,观察两组治疗12周后空腹血糖、餐后2小时血糖、HbA1c,胰岛素用量、低血糖发生次数等指标的差异。结果两组HbA1c水平相似,诺和锐30组控制空腹血糖优于优泌乐50组;优泌乐50组餐后血糖控制优于诺和锐30组,差异有统计学意义(P<0.05)。两组低血糖发生的总次数差异无显著意义P>0.05,但优泌乐50组在白天出现低血糖次数多于诺和锐30组(P<0.05),诺和锐30组在夜间或晨起发生低血糖的次数明显多于优泌乐50(P<0.05)。结论诺和锐30和优泌乐50治疗2型糖尿病疗效肯定,诺和锐30控制空腹血糖存在优势,优泌乐50对餐后血糖的控制存在优势。
Eighty patients with type 2 diabetes mellitus were randomly divided into Nuo-Rui-Rui 30 and You-Zhuo-Le 50, and the fasting blood glucose, 2-hour postprandial blood glucose, HbA1c, insulin dosage and the number of hypoglycemia difference. Results The levels of HbA1c in both groups were similar, and Novo-Rui-30 control of fasting blood glucose was better than that of Youguole 50 groups. The postprandial glycemic control of Yubile-50 group was better than that of Novo-Rui-Ruo 30 group (P <0.05) . There was no significant difference in the total number of hypoglycemia between the two groups (P> 0.05), but there were more hypoglycemic episodes during the day in the 50 groups than those in the Novo group (P <0.05) The incidence of hypoglycemia was significantly higher than that of Urogenital 50 (P <0.05). Conclusions Nuo-Rui-Ru-30 and You-Zhu-Le-50 are effective in treating type 2 diabetes. Novo-Rui-30 has the advantage of controlling fasting blood glucose.